US Stock MarketDetailed Quotes

MRK Merck & Co

Watchlist
  • 127.990
  • +0.490+0.38%
Close Jun 18 16:00 ET
  • 127.990
  • 0.0000.00%
Post 19:58 ET
324.17BMarket Cap142.21P/E (TTM)

Merck & Co Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
(Q2)Jun 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
130.77%3.09B
-31.89%13.01B
-94.45%246M
37.75%7.72B
-13.90%3.7B
-71.88%1.34B
45.52%19.1B
-13.05%4.43B
16.78%5.6B
116.18%4.3B
Net income from continuing operations
68.74%4.77B
-97.40%377M
-140.62%-1.23B
46.06%4.75B
-251.23%-5.97B
-34.41%2.83B
17.54%14.53B
-21.08%3.02B
-28.86%3.25B
225.29%3.95B
Operating gains losses
68.22%-143M
-123.96%-340M
-272.41%-100M
-90.81%34M
-37.81%176M
-163.56%-450M
173.14%1.42B
114.32%58M
154.33%370M
201.07%283M
Depreciation and amortization
-0.71%984M
-0.95%3.87B
8.07%964M
5.74%1.01B
-3.73%903M
-11.52%991M
21.62%3.91B
6.83%892M
26.35%959M
28.85%938M
Deferred tax
81.59%-51M
-21.11%-1.9B
-203.26%-931M
49.17%-336M
-35.50%-355M
18.05%-277M
-938.50%-1.57B
-293.08%-307M
-66,000.00%-661M
-2,481.82%-262M
Other non cash items
-25.73%739M
804.23%11.76B
240.15%449M
-126.76%-99M
1,488.26%10.42B
595.80%995M
-44.90%1.3B
-56.86%132M
116.37%370M
-60.19%656M
Change In working capital
-17.02%-3.38B
20.74%-2.21B
141.50%144M
727.76%2.18B
-16.94%-1.64B
-122.48%-2.89B
27.53%-2.78B
-671.11%-347M
289.21%263M
4.37%-1.4B
-Change in receivables
----
-78.26%-1.15B
----
----
----
----
68.32%-644M
----
----
----
-Change in inventory
----
-406.83%-816M
----
----
----
----
76.11%-161M
----
----
----
-Change in payables and accrued expense
----
3,843.90%1.62B
----
----
----
----
-71.13%41M
----
----
----
-Change in other current liabilities
----
183.67%456M
----
----
----
----
-212.60%-545M
----
----
----
-Change in other working capital
----
-57.09%-2.31B
----
----
----
----
16.21%-1.47B
----
----
----
Cash from discontinued investing activities
0
0
Operating cash flow
130.77%3.09B
-31.89%13.01B
-94.45%246M
37.75%7.72B
-13.90%3.7B
-71.88%1.34B
35.34%19.1B
-11.95%4.43B
16.78%5.6B
72.77%4.3B
Investing cash flow
Cash flow from continuing investing activities
41.67%-1.38B
-183.93%-14.08B
103.03%53M
65.28%-334M
-962.49%-11.44B
-101.11%-2.36B
69.79%-4.96B
85.49%-1.75B
9.33%-962M
58.97%-1.08B
Capital expenditure reported
14.50%-861M
11.96%-3.86B
13.93%-989M
19.89%-902M
14.53%-965M
-2.34%-1.01B
1.35%-4.39B
4.88%-1.15B
3.92%-1.13B
-14.50%-1.13B
Net business purchase and sale
43.78%-746M
-9,843.80%-12.03B
--0
--0
---10.71B
---1.33B
99.06%-121M
--0
-12,200.00%-121M
--0
Net investment purchase and sale
495.16%245M
482.61%1.85B
320.54%1.06B
77.88%587M
550.00%260M
83.29%-62M
-147.12%-483M
-191.12%-482M
197.30%330M
--40M
Net other investing changes
-137.84%-14M
-212.50%-36M
82.05%-21M
57.78%-19M
-375.00%-33M
-79.67%37M
135.16%32M
-10.38%-117M
-4,400.00%-45M
140.00%12M
Cash from discontinued investing activities
Investing cash flow
41.67%-1.38B
-183.93%-14.08B
103.03%53M
65.28%-334M
-962.49%-11.44B
-101.11%-2.36B
70.04%-4.96B
85.49%-1.75B
9.33%-962M
60.21%-1.08B
Financing cash flow
Cash flow from continuing financing activities
-37.00%-2.81B
47.25%-4.81B
-44.47%-2.25B
-57.99%-4.27B
311.48%3.76B
33.44%-2.05B
-394.45%-9.12B
-129.84%-1.55B
-18.82%-2.7B
-178.56%-1.78B
Net issuance payments of debt
-75,000.00%-751M
285.87%4.18B
-200.00%-3M
-94.50%-1.95B
--6.13B
99.92%-1M
-238.01%-2.25B
-100.01%-1M
---1B
--0
Net common stock issuance
18.12%-122M
---1.35B
---393M
---466M
---338M
---149M
--0
--0
--0
--0
Cash dividends paid
-5.23%-1.95B
-6.18%-7.45B
-5.83%-1.85B
-6.18%-1.86B
-6.50%-1.89B
-6.19%-1.85B
-6.08%-7.01B
-6.51%-1.75B
-5.94%-1.75B
-5.80%-1.77B
Proceeds from stock option exercised by employees
190.00%87M
-67.45%125M
-97.74%6M
-30.00%7M
-15.46%82M
150.00%30M
90.10%384M
97.76%265M
-41.18%10M
130.95%97M
Net other financing activities
3.70%-78M
-36.67%-328M
95.59%-3M
-128.57%-10M
-125.00%-234M
21.36%-81M
-102.75%-240M
-106.06%-68M
159.32%35M
-101.17%-104M
Cash from discontinued financing activities
0
0
Financing cash flow
-37.00%-2.81B
47.25%-4.81B
-44.47%-2.25B
-57.99%-4.27B
311.48%3.76B
33.44%-2.05B
-451.68%-9.12B
-129.84%-1.55B
-18.82%-2.7B
-201.08%-1.78B
Net cash flow
Beginning cash position
-45.91%6.91B
56.40%12.77B
-23.14%8.67B
-41.43%5.71B
13.61%9.79B
56.40%12.77B
0.17%8.17B
12.27%11.28B
13.01%9.75B
25.17%8.61B
Current changes in cash
64.22%-1.1B
-217.36%-5.89B
-272.52%-1.95B
60.68%3.11B
-374.93%-3.98B
-712.35%-3.07B
3,312.24%5.02B
162.29%1.13B
32.56%1.94B
-6.04%1.45B
Effect of exchange rate changes
-258.62%-138M
105.61%23M
-49.18%186M
61.89%-157M
69.90%-93M
258.18%87M
-208.27%-410M
638.24%366M
-795.65%-412M
-496.15%-309M
End cash Position
-42.05%5.67B
-45.91%6.91B
-45.91%6.91B
-23.14%8.67B
-41.43%5.71B
13.61%9.79B
56.40%12.77B
56.40%12.77B
12.27%11.28B
13.01%9.75B
Free cash flow
571.39%2.23B
-37.83%9.14B
-122.65%-743M
52.26%6.82B
-13.68%2.74B
-91.21%332M
52.23%14.71B
-14.18%3.28B
23.48%4.48B
110.97%3.17B
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022(Q2)Jun 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 130.77%3.09B-31.89%13.01B-94.45%246M37.75%7.72B-13.90%3.7B-71.88%1.34B45.52%19.1B-13.05%4.43B16.78%5.6B116.18%4.3B
Net income from continuing operations 68.74%4.77B-97.40%377M-140.62%-1.23B46.06%4.75B-251.23%-5.97B-34.41%2.83B17.54%14.53B-21.08%3.02B-28.86%3.25B225.29%3.95B
Operating gains losses 68.22%-143M-123.96%-340M-272.41%-100M-90.81%34M-37.81%176M-163.56%-450M173.14%1.42B114.32%58M154.33%370M201.07%283M
Depreciation and amortization -0.71%984M-0.95%3.87B8.07%964M5.74%1.01B-3.73%903M-11.52%991M21.62%3.91B6.83%892M26.35%959M28.85%938M
Deferred tax 81.59%-51M-21.11%-1.9B-203.26%-931M49.17%-336M-35.50%-355M18.05%-277M-938.50%-1.57B-293.08%-307M-66,000.00%-661M-2,481.82%-262M
Other non cash items -25.73%739M804.23%11.76B240.15%449M-126.76%-99M1,488.26%10.42B595.80%995M-44.90%1.3B-56.86%132M116.37%370M-60.19%656M
Change In working capital -17.02%-3.38B20.74%-2.21B141.50%144M727.76%2.18B-16.94%-1.64B-122.48%-2.89B27.53%-2.78B-671.11%-347M289.21%263M4.37%-1.4B
-Change in receivables -----78.26%-1.15B----------------68.32%-644M------------
-Change in inventory -----406.83%-816M----------------76.11%-161M------------
-Change in payables and accrued expense ----3,843.90%1.62B-----------------71.13%41M------------
-Change in other current liabilities ----183.67%456M-----------------212.60%-545M------------
-Change in other working capital -----57.09%-2.31B----------------16.21%-1.47B------------
Cash from discontinued investing activities 00
Operating cash flow 130.77%3.09B-31.89%13.01B-94.45%246M37.75%7.72B-13.90%3.7B-71.88%1.34B35.34%19.1B-11.95%4.43B16.78%5.6B72.77%4.3B
Investing cash flow
Cash flow from continuing investing activities 41.67%-1.38B-183.93%-14.08B103.03%53M65.28%-334M-962.49%-11.44B-101.11%-2.36B69.79%-4.96B85.49%-1.75B9.33%-962M58.97%-1.08B
Capital expenditure reported 14.50%-861M11.96%-3.86B13.93%-989M19.89%-902M14.53%-965M-2.34%-1.01B1.35%-4.39B4.88%-1.15B3.92%-1.13B-14.50%-1.13B
Net business purchase and sale 43.78%-746M-9,843.80%-12.03B--0--0---10.71B---1.33B99.06%-121M--0-12,200.00%-121M--0
Net investment purchase and sale 495.16%245M482.61%1.85B320.54%1.06B77.88%587M550.00%260M83.29%-62M-147.12%-483M-191.12%-482M197.30%330M--40M
Net other investing changes -137.84%-14M-212.50%-36M82.05%-21M57.78%-19M-375.00%-33M-79.67%37M135.16%32M-10.38%-117M-4,400.00%-45M140.00%12M
Cash from discontinued investing activities
Investing cash flow 41.67%-1.38B-183.93%-14.08B103.03%53M65.28%-334M-962.49%-11.44B-101.11%-2.36B70.04%-4.96B85.49%-1.75B9.33%-962M60.21%-1.08B
Financing cash flow
Cash flow from continuing financing activities -37.00%-2.81B47.25%-4.81B-44.47%-2.25B-57.99%-4.27B311.48%3.76B33.44%-2.05B-394.45%-9.12B-129.84%-1.55B-18.82%-2.7B-178.56%-1.78B
Net issuance payments of debt -75,000.00%-751M285.87%4.18B-200.00%-3M-94.50%-1.95B--6.13B99.92%-1M-238.01%-2.25B-100.01%-1M---1B--0
Net common stock issuance 18.12%-122M---1.35B---393M---466M---338M---149M--0--0--0--0
Cash dividends paid -5.23%-1.95B-6.18%-7.45B-5.83%-1.85B-6.18%-1.86B-6.50%-1.89B-6.19%-1.85B-6.08%-7.01B-6.51%-1.75B-5.94%-1.75B-5.80%-1.77B
Proceeds from stock option exercised by employees 190.00%87M-67.45%125M-97.74%6M-30.00%7M-15.46%82M150.00%30M90.10%384M97.76%265M-41.18%10M130.95%97M
Net other financing activities 3.70%-78M-36.67%-328M95.59%-3M-128.57%-10M-125.00%-234M21.36%-81M-102.75%-240M-106.06%-68M159.32%35M-101.17%-104M
Cash from discontinued financing activities 00
Financing cash flow -37.00%-2.81B47.25%-4.81B-44.47%-2.25B-57.99%-4.27B311.48%3.76B33.44%-2.05B-451.68%-9.12B-129.84%-1.55B-18.82%-2.7B-201.08%-1.78B
Net cash flow
Beginning cash position -45.91%6.91B56.40%12.77B-23.14%8.67B-41.43%5.71B13.61%9.79B56.40%12.77B0.17%8.17B12.27%11.28B13.01%9.75B25.17%8.61B
Current changes in cash 64.22%-1.1B-217.36%-5.89B-272.52%-1.95B60.68%3.11B-374.93%-3.98B-712.35%-3.07B3,312.24%5.02B162.29%1.13B32.56%1.94B-6.04%1.45B
Effect of exchange rate changes -258.62%-138M105.61%23M-49.18%186M61.89%-157M69.90%-93M258.18%87M-208.27%-410M638.24%366M-795.65%-412M-496.15%-309M
End cash Position -42.05%5.67B-45.91%6.91B-45.91%6.91B-23.14%8.67B-41.43%5.71B13.61%9.79B56.40%12.77B56.40%12.77B12.27%11.28B13.01%9.75B
Free cash flow 571.39%2.23B-37.83%9.14B-122.65%-743M52.26%6.82B-13.68%2.74B-91.21%332M52.23%14.71B-14.18%3.28B23.48%4.48B110.97%3.17B
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --Unqualified Opinion--------Unqualified Opinion------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg
Concept Cancer Research
Cancer Research
Intraday+0.20%
ESG Investing
ESG Investing
Intraday-0.62%